These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 25164220)
21. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Barst RJ; Ivy DD; Foreman AJ; McGoon MD; Rosenzweig EB Am J Cardiol; 2014 Jan; 113(1):147-55. PubMed ID: 24176071 [TBL] [Abstract][Full Text] [Related]
22. Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects. Li Q; Dimopoulos K; Zhang C; Zhu Y; Liu Q; Gu H Pediatr Cardiol; 2018 Apr; 39(4):757-762. PubMed ID: 29426959 [TBL] [Abstract][Full Text] [Related]
23. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Yurtseven N; Karaca P; Uysal G; Ozkul V; Cimen S; Tuygun AK; Yuksek A; Canik S Ann Thorac Cardiovasc Surg; 2006 Oct; 12(5):319-23. PubMed ID: 17095973 [TBL] [Abstract][Full Text] [Related]
24. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008 [TBL] [Abstract][Full Text] [Related]
25. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Reichenberger F; Mainwood A; Doughty N; Fineberg A; Morrell NW; Pepke-Zaba J Respir Med; 2007 Feb; 101(2):217-22. PubMed ID: 16831539 [TBL] [Abstract][Full Text] [Related]
26. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158 [TBL] [Abstract][Full Text] [Related]
27. Hemodynamic effects of combination therapy with inhaled nitric oxide and iloprost in patients with pulmonary hypertension and right ventricular dysfunction after high-risk cardiac surgery. Antoniou T; Koletsis EN; Prokakis C; Rellia P; Thanopoulos A; Theodoraki K; Zarkalis D; Sfyrakis P J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):459-66. PubMed ID: 23063102 [TBL] [Abstract][Full Text] [Related]
28. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. Launay D; Hachulla E; Hatron PY; Goullard L; Onimus T; Robin S; Fauchais AL; Queyrel V; Michon-Pasturel U; Hebbar M; Saulnier F; Devulder B J Rheumatol; 2001 Oct; 28(10):2252-6. PubMed ID: 11669165 [TBL] [Abstract][Full Text] [Related]
29. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension. Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465 [TBL] [Abstract][Full Text] [Related]
30. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study). D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546 [TBL] [Abstract][Full Text] [Related]
31. Long-term inhaled iloprost use in children with pulmonary arterial hypertension. Alehan D; Yıldırım I; Sahin M; Ozkutlu S; Ozer S; Karagöz T Cardiol Young; 2012 Aug; 22(4):396-403. PubMed ID: 22067137 [TBL] [Abstract][Full Text] [Related]
32. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496 [TBL] [Abstract][Full Text] [Related]
33. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study. Jiang X; Wang YF; Zhao QH; Jiang R; Wu Y; Peng FH; Xu XQ; Wang L; He J; Jing ZC Int J Cardiol; 2014 Nov; 177(1):61-5. PubMed ID: 25499341 [TBL] [Abstract][Full Text] [Related]
34. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. Durongpisitkul K; Jakrapanichakul D; Sompradikul S J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984 [TBL] [Abstract][Full Text] [Related]
35. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050 [TBL] [Abstract][Full Text] [Related]
36. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Kramm T; Eberle B; Guth S; Mayer E Eur J Cardiothorac Surg; 2005 Dec; 28(6):882-8. PubMed ID: 16242948 [TBL] [Abstract][Full Text] [Related]
37. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Sablotzki A; Czeslick E; Schubert S; Friedrich I; Mühling J; Dehne MG; Grond S; Hentschel T Can J Anaesth; 2002 Dec; 49(10):1076-80. PubMed ID: 12477682 [TBL] [Abstract][Full Text] [Related]
38. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Garg N; Sharma MK; Sinha N Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417 [TBL] [Abstract][Full Text] [Related]